Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.

Author: , Al-KhatibSana M, AlexanderJohn H, AlingsMarco, AmerenaJohn, AnsellJack, AylwardPhilip, BartunekJozef, CommerfordPatrick, De CaterinaRaffaele, ErolCetin, GrangerChristopher B, HannaMichael, HarjolaVeli-Pekka, HeldClaes, HellkampAnne, HorowitzJohn D, HuberKurt, HustedSteen, HylekElaine M, KeltaiMatyas, LanasFernando, LishengLiu, LopesRenato D, McMurrayJohn J V, NepalSunil, OhByung-Hee, RosenqvistMårten, RuzylloWitold, StegPhilippe Gabriel, ThomasLaine, VinereanuDragos, WallentinLars, XavierDenis

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This analysis of the ARISTOTLE trial, which compared apixaban to warfarin for stroke prevention in atrial fibrillation, examined treatment effects in relation to time in therapeutic range (TTR). The findings indicate that apixaban may provide benefits regardless of TTR, while warfarin's effectiveness is more dependent on TTR.
Paper Details　
Original Abstract of the Article :
In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and mortality. We evaluated treatment effects in relation to 2 predictions of time in therapeutic ra...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1161/CIRCULATIONAHA.112.142158

データ提供：米国国立医学図書館（NLM）

A New Hope for Stroke Prevention in Atrial Fibrillation

The field of cardiovascular health is always striving to find better ways to prevent strokes, especially in patients with atrial fibrillation. This research delves into the world of anticoagulants, specifically comparing apixaban to warfarin. The study, known as the ARISTOTLE trial, utilized a rigorous approach, analyzing the effectiveness of these medications based on time in therapeutic range (TTR) predictions. The authors discovered that apixaban outperformed warfarin in reducing stroke and systemic embolism, as well as major bleeding and mortality. This discovery highlights the potential of apixaban as a more effective and safer option for stroke prevention in atrial fibrillation.

Apixaban: A Step Forward for Stroke Prevention?

The findings suggest that apixaban may be a superior choice for stroke prevention in patients with atrial fibrillation. The study's results demonstrate a significant reduction in stroke, systemic embolism, major bleeding, and overall mortality compared to warfarin. These findings could have profound implications for the treatment of atrial fibrillation, leading to improved patient outcomes.

A New Era for Atrial Fibrillation Management

These results are encouraging news for patients with atrial fibrillation, a condition that can significantly increase the risk of stroke. Apixaban, with its demonstrated efficacy and safety profile, offers a potential new pathway for managing this condition. It's important to consult your doctor for personalized advice and to understand the specific benefits and risks associated with apixaban.

Dr.Camel's Conclusion

The ARISTOTLE trial sheds light on the potential of apixaban for stroke prevention in patients with atrial fibrillation. It's like finding a refreshing oasis in a vast, unforgiving desert - a beacon of hope for improved treatment outcomes. The study's findings suggest that apixaban may be a game-changer, leading to a more effective and safer approach to managing this challenging condition.

Date :
  1. Date Completed 2013-08-06
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

23640971

DOI: Digital Object Identifier

10.1161/CIRCULATIONAHA.112.142158

Related Literature

Article Analysis
・Effects of apixaban・Effects of acalabrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.